Strongbridge Biopharma Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
72
- Latest Deal Type
-
M&A
- Financing Rounds
-
9
- Investments
-
3
Strongbridge Biopharma General Information
Description
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
Contact Information
Website
www.strongbridgebio.comCorporate Office
- 900 Northbrook Drive
- Suite 200
- Trevose, PA 19053
- United States
Corporate Office
- 900 Northbrook Drive
- Suite 200
- Trevose, PA 19053
- United States
Strongbridge Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Strongbridge Biopharma Comparisons
Industry
Financing
Details
Strongbridge Biopharma Competitors (34)
One of Strongbridge Biopharma’s 34 competitors is Rallybio, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rallybio | Formerly VC-backed | New Haven, CT | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Santhera Pharmaceuticals Holding | Formerly VC-backed | Pratteln, Switzerland | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA |
Strongbridge Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Strongbridge Biopharma Patents
Strongbridge Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12758502-B2 | Compositions and methods of use | Active | 18-Jun-2019 | ||
| AU-2020296816-A1 | Dichlorphenamide compositions and methods of use | Inactive | 18-Jun-2019 | ||
| CA-3143958-A1 | Dichlorphenamide compositions and methods of use | Pending | 18-Jun-2019 | ||
| EP-3972579-A1 | Dichlorphenamide compositions and methods of use | Inactive | 18-Jun-2019 | ||
| EP-3972579-A4 | Dichlorphenamide compositions and methods of use | Inactive | 18-Jun-2019 | A61K9/2077 |
Strongbridge Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Strongbridge Biopharma Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Strongbridge Biopharma Investments & Acquisitions (3)
Strongbridge Biopharma’s most recent deal was a Corporate Asset Purchase with MACRILEN (US and Canada Rights) for . The deal was made on 16-Jan-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MACRILEN (US and Canada Rights) | 16-Jan-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Keveyis (U.S. rights) | 23-Dec-2016 | Corporate Asset Purchase | Buildings and Property | ||
| Aspireo Pharmaceuticals | 30-Jun-2015 | Merger/Acquisition | Drug Discovery |
Strongbridge Biopharma Exits (1)
Strongbridge Biopharma’s most recent exit was on 16-Jan-2018 from MACRILEN (US and Canada Rights). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MACRILEN (US and Canada Rights) | 16-Jan-2018 | Completed |
|
Strongbridge Biopharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Strongbridge Ireland | Trevose, PA | 2017 |
Strongbridge Biopharma FAQs
-
When was Strongbridge Biopharma founded?
Strongbridge Biopharma was founded in 1996.
-
Where is Strongbridge Biopharma headquartered?
Strongbridge Biopharma is headquartered in Trevose, PA.
-
What is the size of Strongbridge Biopharma?
Strongbridge Biopharma has 72 total employees.
-
What industry is Strongbridge Biopharma in?
Strongbridge Biopharma’s primary industry is Pharmaceuticals.
-
Is Strongbridge Biopharma a private or public company?
Strongbridge Biopharma is a Private company.
-
What is the current valuation of Strongbridge Biopharma?
The current valuation of Strongbridge Biopharma is .
-
What is Strongbridge Biopharma’s current revenue?
The current revenue for Strongbridge Biopharma is .
-
How much funding has Strongbridge Biopharma raised over time?
Strongbridge Biopharma has raised $159M.
-
Who are Strongbridge Biopharma’s investors?
AP Fonden 3, Acuta Capital Partners, Arctic Capital (Oslo), Birk Venture, and Broadfin Capital are 5 of 14 investors who have invested in Strongbridge Biopharma.
-
Who are Strongbridge Biopharma’s competitors?
Rallybio, Crinetics Pharmaceuticals, Santhera Pharmaceuticals Holding, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals are some of the 34 competitors of Strongbridge Biopharma.
-
When was Strongbridge Biopharma acquired?
Strongbridge Biopharma was acquired on 05-Oct-2021.
-
Who acquired Strongbridge Biopharma?
Strongbridge Biopharma was acquired by Xeris Biopharma Holdings.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
